QQQ   280.77 (-0.32%)
AAPL   141.71 (-0.84%)
MSFT   244.00 (-0.46%)
META   113.12 (-0.88%)
GOOGL   96.40 (-0.60%)
AMZN   88.55 (+0.34%)
TSLA   175.18 (-2.58%)
NVDA   158.73 (-0.71%)
NIO   12.59 (-4.91%)
BABA   87.59 (-4.22%)
AMD   69.70 (-0.81%)
T   19.12 (-0.26%)
MU   53.27 (-0.76%)
CGC   3.58 (-0.83%)
F   13.23 (-0.38%)
DIS   92.85 (+0.61%)
AMC   6.79 (+0.59%)
PYPL   72.00 (-0.32%)
NFLX   303.92 (-0.54%)
QQQ   280.77 (-0.32%)
AAPL   141.71 (-0.84%)
MSFT   244.00 (-0.46%)
META   113.12 (-0.88%)
GOOGL   96.40 (-0.60%)
AMZN   88.55 (+0.34%)
TSLA   175.18 (-2.58%)
NVDA   158.73 (-0.71%)
NIO   12.59 (-4.91%)
BABA   87.59 (-4.22%)
AMD   69.70 (-0.81%)
T   19.12 (-0.26%)
MU   53.27 (-0.76%)
CGC   3.58 (-0.83%)
F   13.23 (-0.38%)
DIS   92.85 (+0.61%)
AMC   6.79 (+0.59%)
PYPL   72.00 (-0.32%)
NFLX   303.92 (-0.54%)
QQQ   280.77 (-0.32%)
AAPL   141.71 (-0.84%)
MSFT   244.00 (-0.46%)
META   113.12 (-0.88%)
GOOGL   96.40 (-0.60%)
AMZN   88.55 (+0.34%)
TSLA   175.18 (-2.58%)
NVDA   158.73 (-0.71%)
NIO   12.59 (-4.91%)
BABA   87.59 (-4.22%)
AMD   69.70 (-0.81%)
T   19.12 (-0.26%)
MU   53.27 (-0.76%)
CGC   3.58 (-0.83%)
F   13.23 (-0.38%)
DIS   92.85 (+0.61%)
AMC   6.79 (+0.59%)
PYPL   72.00 (-0.32%)
NFLX   303.92 (-0.54%)
QQQ   280.77 (-0.32%)
AAPL   141.71 (-0.84%)
MSFT   244.00 (-0.46%)
META   113.12 (-0.88%)
GOOGL   96.40 (-0.60%)
AMZN   88.55 (+0.34%)
TSLA   175.18 (-2.58%)
NVDA   158.73 (-0.71%)
NIO   12.59 (-4.91%)
BABA   87.59 (-4.22%)
AMD   69.70 (-0.81%)
T   19.12 (-0.26%)
MU   53.27 (-0.76%)
CGC   3.58 (-0.83%)
F   13.23 (-0.38%)
DIS   92.85 (+0.61%)
AMC   6.79 (+0.59%)
PYPL   72.00 (-0.32%)
NFLX   303.92 (-0.54%)
NASDAQ:INO

Inovio Pharmaceuticals - INO Stock Forecast, Price & News

$1.79
-0.06 (-3.24%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.77
$1.84
50-Day Range
$1.56
$2.50
52-Week Range
$1.38
$6.74
Volume
5.02 million shs
Average Volume
6.26 million shs
Market Capitalization
$446.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Inovio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
1.86 Rating Score
Upside/​Downside
109.5% Upside
$3.75 Price Target
Short Interest
Bearish
18.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
1.33mentions of Inovio Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.10) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

681st out of 1,023 stocks

Surgical & Medical Instruments Industry

74th out of 102 stocks

INO stock logo

About Inovio Pharmaceuticals (NASDAQ:INO) Stock

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Stock News Headlines

INOVIO Provides an Update on Lassa Fever and MERS Programs
3 Stocks to Avoid Right Now
Why Inovio Pharmaceuticals Stock Is Popping Off
What's Going On With Inovio Pharmaceuticals Stock Tuesday After Hours
Inovio Pharmaceuticals Inc. Q3 Loss decreases, beats estimates
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Company Calendar

Last Earnings
11/08/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
317
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+109.5%
Consensus Rating
Hold
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-303,660,000.00
Net Margins
-3,027.10%
Pretax Margin
-3,007.81%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.90 per share

Miscellaneous

Free Float
241,256,000
Market Cap
$446.59 million
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 56)
    CEO, Pres & Director
    Comp: $698.85k
  • Mr. Peter D. KiesMr. Peter D. Kies (Age 59)
    Chief Financial Officer
    Comp: $686.51k
  • Dr. Laurent M. Humeau Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $672.26k
  • Ben Matone
    Director of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 48)
    Gen. Counsel
  • Ms. Asli Gevgilili
    Chief HR Officer
  • Mr. E. J. Brandreth MBA
    Sr. VP of Quality Assurance
  • Dr. Jeffrey Skolnik
    Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr.
    Sr. VP of Biological Manufacturing & Clinical Supply Management
  • Mr. Daniel Jordan
    Sr. VP of Device Manufacturing Operations













INO Stock - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price forecast for 2023?

7 brokerages have issued 1 year price targets for Inovio Pharmaceuticals' stock. Their INO share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 109.5% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2022?

Inovio Pharmaceuticals' stock was trading at $4.99 on January 1st, 2022. Since then, INO shares have decreased by 64.1% and is now trading at $1.79.
View the best growth stocks for 2022 here
.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 46,150,000 shares, an increase of 5.7% from the October 31st total of 43,670,000 shares. Based on an average daily trading volume, of 5,820,000 shares, the days-to-cover ratio is presently 7.9 days.
View Inovio Pharmaceuticals' Short Interest
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our INO earnings forecast
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. The biopharmaceutical company earned $9.15 million during the quarter, compared to analysts' expectations of $0.53 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 100.75% and a negative net margin of 3,027.10%. The company's quarterly revenue was up 3034.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.29) earnings per share.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (10.43%), BlackRock Inc. (8.64%), Vanguard Group Inc. (6.17%), Renaissance Technologies LLC (0.93%), Two Sigma Advisers LP (0.91%) and Two Sigma Investments LP (0.76%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $1.79.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $446.59 million and generates $1.77 million in revenue each year. The biopharmaceutical company earns $-303,660,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

The company employs 317 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 12/7/2022 by MarketBeat.com Staff